For the Quarter Ending March 2026
听
Metformin HCL Prices in听APAC
- In South Korea, the Metformin Hydrochloride Price Index rose by 2.41% quarter-over-quarter, reflecting tighter March supply.
- The average Metformin Hydrochloride price for the quarter was approximately USD 2652.33/MT, reported by importers and distributors.
- Metformin Hydrochloride Spot Price tightened in March as Chinese and Indian allocations prioritized domestic and US contracts.
- Metformin Hydrochloride Price Forecast indicates April increases driven by restocking, inventory drawdowns, and freight cost pressures overall.
- Metformin Hydrochloride Production Cost Trend rose from LNG-linked utility increases, lifting Chinese FOB quotations and Busan costs.
- Metformin Hydrochloride Demand Outlook remains steady as NHIS reimbursement support and chronic-disease prescriptions sustain baseline consumption levels.
- Distributor inventories tightened to around four weeks, supporting the Metformin Hydrochloride Price Index and firmer dealer offers.
- Chinese plant documentation upgrades and Indian US-bound shipments reduced export surplus, amplifying Busan Price Index pressure.
Why did the price of Metformin Hydrochloride change in March 2026 in APAC?
- Export supply tightened as Chinese documentation upgrades and Indian shipments diverted to the US reduced Korean allotments.
- LNG price rebound raised Chinese utility costs, lifting FOB offers and increasing landed import costs into Busan.
- Korean formulators advanced orders ahead of NHIS reimbursement review, thereby intensifying competition for the limited March parcel availability.
听
Metformin HCL Prices in听Europe
- In Germany, the Metformin Price Index rose by 2.95% quarter-over-quarter, reflecting tighter post-nitrosamine availability recently.
- The average Metformin price for the quarter was approximately USD 2742.00/MT across import and domestic supply channels.
- Metformin Spot Price tightened in March as distributors reduced available lots, supporting firmer offers nationwide.
- Metformin Price Forecast indicates modest gains near-term, supported by selective restocking and tighter shipments abroad.
- Metformin Production Cost Trend showed upward pressure from higher Asian FOBs, freight, and raw-material expenses.
- Metformin Demand Outlook remains structurally firm due to the ageing population and steady reimbursed prescription volumes.
- Metformin Price Index volatility is limited by AMNOG reference pricing, constraining pass-through of upstream cost increases.
- Inventory levels stayed around three weeks, preventing shortages while port operations in Hamburg remained smooth.
Why did the price of Metformin change in March 2026 in Europe?
- Tighter imported availability due to extended-release testing and documentation reduced spot cargoes into Hamburg.
- Elevated freight and higher Asian FOB quotations increased landed costs, prompting importers to accelerate purchases.
- Robust domestic offtake from formulators and hospital tendering absorbed volumes, limiting downward pressure on prices.
听
Metformin HCL Prices in听North America
- In the USA, the Metformin Price Index rose quarter-over-quarter, reflecting tighter import availability and firm underlying demand.
- Metformin Spot Price strengthened in March as reduced shipment availability and distributor inventory control tightened prompt supply.
- Metformin Production Cost Trend showed upward pressure, driven by higher Asian FOB prices, freight costs, and raw material expenses.
- Metformin Demand Outlook remained structurally strong, supported by consistent prescription volumes and ongoing demand from the healthcare sector.
- Metformin Price Forecast indicates modest near-term gains, driven by restocking activity and constrained import flows.
- Inventory levels across US distribution channels remained adequate but slightly tighter due to steady consumption and delayed replenishment.
- Import reliance on Asian suppliers exposed the market to supply constraints linked to compliance and extended testing requirements.
- Suppliers maintained firm pricing discipline, balancing cost increases with steady demand and controlled inventory releases.
Why did the price of Metformin change in March 2026 in North America?
- Reduced export availability due to extended testing and documentation requirements limited incoming shipments.
- Higher freight rates and increased Asian FOB prices raised landed import costs.
- Strong domestic demand from formulators and healthcare procurement absorbed supply, supporting firmer pricing.
For the Quarter Ending December 2025
APAC
- In South Korea, the Metformin HCL Price Index fell by 0.61% quarter-over-quarter, reflecting feedstock pressure.
- The average Metformin HCL price for the quarter was approximately USD 3982.00/MT, reported CFR Busan.
- Metformin HCL Spot Price remained muted as steady imports and balanced inventories constrained supplier offers.
- Metformin HCL Price Forecast expects modest initial weakness followed by recovery driven by selective restocking.
- Metformin HCL Production Cost Trend showed mild upward pressure from energy and intermediate feedstock costs.
- Metformin HCL Demand Outlook remains steady as diabetes prevalence supports consumption and disciplined procurement continues.
- Metformin HCL Price Index benefited from Busan logistics and competitive Chinese and Indian export offers.
- Distributor inventories and balanced domestic output limited urgent buying, restraining spikes, and preserving market balance.
Why did the price of Metformin HCL change in December 2025 in APAC?
- Balanced imports from China and India met steady demand, keeping December price movement slightly negative.
- Stable freight and Busan port operations removed logistics premiums, preventing landed cost pressure on offers.
- Comfortable inventories and disciplined procurement by manufacturers limited spot buying, curbing upward price momentum in December.
Europe
- In Germany, the Metformin Price Index fell by 0.79% quarter-over-quarter, reflecting steady imports and procurement.
- The average Metformin price for the quarter was approximately USD 4053.00/MT, reflecting range-bound traded levels.
- Metformin Spot Price movements were subdued as abundant Asian shipments and distributor buying limited volatility.
- Metformin Price Forecast projects modest weakness early Q1 due to inventory overhang and spot purchasing.
- Metformin Production Cost Trend showed upward pressure from feedstock and energy, affecting landed CFR Hamburg costs.
- Metformin Demand Outlook remains stable with steady pharmaceutical offtake, restrained spot buying, and predictable prescription-driven consumption.
- Metformin Price Index reflected mild downward pressure as reference-price caps and tendering capped seller leverage.
- Inventory buffers and export flows from India and China limited restocking, keeping short-term offers subdued.
Why did the price of Metformin change in December 2025 in Europe?
- Ample imports from India and China matched demand, creating inventory overhang and reducing seller pricing power.
- Reference-price caps and completed year-end tenders restrained formulators, limiting spot buying and post-holiday procurement activity.
- Moderate feedstock and freight pressures marginally lowered landed costs, not triggering significant upward price movement.
North America
- In North America, the Metformin Price Index declined slightly quarter-over-quarter, reflecting stable import flows and measured procurement.
- Metformin market conditions remained import-led, with India and China supplying most shipments for pharmaceutical distributors and hospitals.
- Metformin Spot Price movements were subdued as abundant Asian-origin cargoes and adequate distributor inventories limited short-term volatility.
- Metformin Price Forecast signals modest weakness early 2026, due to inventory overhang and cautious year-end purchasing by formulators.
- Metformin Production Cost Trend for importers showed moderate upward pressure from feedstock and energy costs, partially offset by stable freight.
- Metformin Demand Outlook remained steady, with routine pharmaceutical offtake and prescription-driven consumption balancing subdued spot buying.
- Price Index reflected mild downward pressure as reference-price caps, tenders, and year-end order timing constrained importer leverage.
- Distributor and hospital inventories remained adequate, preventing urgent restocking and maintaining near-term price stability.
Why did the price of Metformin change in December 2025 in North America?
- Ample imports from India and China met demand, creating inventory overhang and limiting spot price gains.
- Reference-price caps and completed year-end tenders restrained formulators, curbing immediate buying activity.
- Moderate feedstock and freight pressures kept landed costs stable, preventing significant upward price movement.
For the Quarter Ending September 2025
APAC
- In South Korea, the Metformin HCL Price Index fell by 14.17% quarter-over-quarter, driven by excess inventories.
- The average Metformin HCL price for the quarter was approximately USD 4006.33/MT, reflecting subdued purchasing activity.
- Metformin HCL Spot Price weakened as Asian export offers softened and landed costs declined, pressuring domestic margins.
- Metformin HCL Price Forecast shows modest volatility with alternating mild declines and brief recoveries through near term.
- Metformin HCL Production Cost Trend eased due to lower raw material costs and favourable USD-KRW movements reducing import expenses.
- Metformin HCL Demand Outlook remains weak with downstream pharmaceuticals and API manufacturers deferring restocking amid ample inventories.
- Export volumes stayed steady while domestic suppliers discounted stock, keeping the Metformin HCL Price Index under downward pressure.
- Major supplier production remained stable, but elevated distributor inventories and cautious procurement constrained upside momentum.
Why did the price of Metformin HCL change in September 2025 in APAC?
- Ample import supplies and discounted Asian export offers increased available volumes, reducing landed costs and price pressure.
- High domestic inventories prompted buyers to delay orders, suppressing procurement and weakening short term demand.
- Lower raw material costs and favourable USD KRW exchange reduced production and import costs, offset slightly by freight.
Europe
- In Germany, the Metformin Price Index fell by 13.08% quarter-over-quarter, driven by import cuts and inventory overhang.
- The average Metformin price for the quarter was approximately USD 4085.33/MT amid subdued procurement activity.
- Metformin Spot Price weakness reflected discounted Asian offers and cautious German buyers delaying replenishment orders.
- Metformin Price Forecast suggests marginal volatility as end-user inquiries slowly recover and inventories normalize gradually.
- Metformin Production Cost Trend benefited from weaker USD and Asian offers, partially offset by freight.
- Metformin Demand Outlook remains muted, keeping Metformin Price Index pressured amid weak pharmaceutical procurement activity.
- Elevated inventories and steady export flows constrained trading, limiting any uptick in Metformin Spot Price.
- Major producers ran steady volumes, limiting disruption risk and supporting balanced Metformin Price Index dynamics.
Why did the price of Metformin change in September 2025 in Europe?
- Abundant Asian export offers and high domestic inventories reduced procurement urgency, driving Metformin downward pressure.
- Weaker USD lowered import costs, while rising freight rates offset savings for landed Metformin shipments.
- Cautious pharmaceutical procurement and soft downstream consumption constrained buying, sustaining weak Metformin Price Index momentum.
North America
- In the USA, the Metformin Price Index declined quarter-over-quarter, reflecting high inventories and weaker import demand from Asia.
- Metformin Spot Price softened as suppliers offered discounts to clear stock, while U.S. buyers delayed orders amid muted pharmaceutical consumption.
- Metformin Price Forecast indicates limited near-term recovery, with expectations of stabilization as downstream restocking resumes gradually.
- Metformin Production Cost Trend for importers eased with lower Asian export quotations and steady freight costs helping moderate landed expenses.
- Metformin Demand Outlook remains subdued, with healthcare and generic drug manufacturers maintaining cautious procurement patterns.
- Elevated inventories and subdued import activity weighed on Metformin Price Index performance across key distribution hubs.
- Competitive pricing among Asian exporters pressured landed cost margins, keeping Metformin Spot Price constrained in the U.S. market.
- Smooth logistics and consistent shipping schedules ensured supply continuity, minimizing volatility despite the weak demand environment.
Why did the price of Metformin change in September 2025 in North America?
- Ample supply from Asian exporters and existing domestic inventories reduced procurement urgency, pushing prices lower.
- Subdued downstream demand and delayed restocking limited transactional activity, maintaining weak market sentiment.
- Stable freight rates and smoother import operations partially offset cost pressures but were insufficient to support price recovery.
For the Quarter Ending June 2025
North America
- In North America (US), the Price Index for Metformin Hydrochloride (USP, FDA) remained on an upward trajectory in July 2025, maintaining the firm momentum seen since late Q2.
- The Spot Price of Metformin Hydrochloride saw steady gains, supported by reduced inventories among major pharmaceutical formulators and continued challenges in securing bulk imports.
- Why did the price of Metformin Hydrochloride change in July 2025?
- The upward movement was primarily attributed to limited supplier offerings from overseas, strong domestic demand for diabetes therapeutics, and tightening logistics for FDA-grade imports.
- The Production Cost Trend for Metformin Hydrochloride in the US remained elevated, influenced by sustained packaging and labor costs, coupled with increased reliance on higher-priced secondary sourcing channels.
- The Demand Outlook for Metformin Hydrochloride in North America remained strong, underpinned by stable prescription volumes, expanding insurance coverage for generic therapeutics, and restocking by hospital buyers.
- The Price Forecast for Metformin Hydrochloride for Q3 2025 indicates further firmness, with expectations of constrained inbound shipments and robust demand from public health procurement programs.
- Importers continued to face lengthened lead times for high-purity Metformin Hydrochloride, resulting in gradual buildup of procurement backlogs among smaller US formulators.
- Market participants reported increased competitiveness in securing forward contracts, with several buyers seeking alternative FDA-approved suppliers to ensure continuity.
- The relatively slow customs clearance and regulatory documentation processes for bulk pharmaceutical ingredients added to lead time challenges across the import cycle.
- The firm Q3 outlook for Metformin Hydrochloride in the US also stems from seasonal upticks in production schedules and pre-holiday order placements from large distribution chains.
Europe
- In Europe (Germany), the Price Index for Metformin Hydrochloride (USP, FDA) CFR Hamburg rose in July 2025, marking a 2.36% increase over the previous month after three months of price decline.
- The Spot Price of Metformin Hydrochloride in Germany increased due to reduced Asian export volumes and improved downstream procurement across the pharmaceutical sector.
- Why did the price change in July 2025?
- The increase was driven by tightening inventory at European ports, limited fresh imports from Asia, and restocking demand by formulation units.
- The Production Cost Trend rose in July, impacted by climbing shipping costs from key producers in China and India, as well as increased packaging and handling charges across the EU.
- The Demand Outlook improved with the onset of Q3 procurement cycles, leading to increased contract activity among German drug formulators.
- The Price Forecast for Q3 2025 indicates a likely continuation of this upward trajectory, supported by constrained global supply and stronger restocking momentum from healthcare manufacturers.
- Additional cost pressure stemmed from regulatory tightening on pharmaceutical-grade API imports, which delayed some shipments and strained local supply.
- Inventory levels remained below the seasonal average across Hamburg and Rotterdam, prompting importers to raise bids to secure short-lead shipments.
- European buyers showed preference for FDA-compliant, USP-grade Metformin Hydrochloride, limiting their supplier base and amplifying price pressure amid lower availability.
- Competitive pressure from non-European sources remained weak as Asian suppliers prioritized domestic fulfillment and high-margin export markets.
APAC
- In APAC (South Korea), the Price Index for Metformin Hydrochloride (USP, FDA) CFR Busan increased in July 2025, marking a reversal from the consistent decline seen in the prior three months.
- The Spot Price of Metformin Hydrochloride rose to USD 4,291/MT in July, reflecting an upward shift driven by limited import supply and restocking by local pharmaceutical manufacturers.
- Why did the price of Metformin Hydrochloride change in July 2025?
- The price increase was driven by tighter export volumes from major Asian producers, currency normalization pressures, and a rebound in short-term procurement activity.
- The Production Cost Trend for Metformin Hydrochloride turned slightly bullish in July, influenced by a rise in freight costs, intermediate raw material prices, and packaging expenses across the Asian region.
- The Demand Outlook for Metformin Hydrochloride in South Korea improved marginally, with downstream formulators ramping up purchases for Q3 delivery cycles amid recovering domestic pharmaceutical output.
- The Price Forecast for Metformin Hydrochloride in August 2025 indicates a potential continuation of the upward trend, supported by depleted inventories and firmer buying interest from end users.
- Availability of Metformin Hydrochloride remained constrained due to export prioritization by Indian and Chinese producers toward higher-margin markets, impacting South Korean shipment volumes.
- Currency movements鈥攕pecifically the firming of the US Dollar鈥攖empered some of the cost advantages previously enjoyed, affecting Metformin Hydrochloride import economics.
- Despite higher ocean freight, lower inventory levels and improved order consistency supported the recent price rebound of Metformin Hydrochloride in South Korea.
- Public sector procurement and institutional buying further contributed to stronger spot market activity for Metformin Hydrochloride, reinforcing the July price recovery.
